Novel coronavirus recombinant chimeric antigen as well as preparation method and application thereof

By connecting the RBD and NTD amino acid sequences of the novel coronavirus to form recombinant chimeric antigens, the problem of weak cross-reaction of existing vaccines to Omicron mutant strains is solved, and the broad-spectrum protection effect on multiple mutant strains is achieved.

CN119060197APending Publication Date: 2024-12-03JIANGSU RECBIO TECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410579155.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-11
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing novel coronavirus vaccine has a strong immune response to the Omicron mutant strain, but has weak cross-reactions to the prototype and other mutant strains, and the prevalent mutant strains change rapidly, making it difficult to provide broad-spectrum protection.

Method used

Develop a recombinant chimeric antigen that forms a broad-spectrum protective immunogen, including Omicron variants, by connecting amino acid sequences from receptor binding regions RBD and N-terminal domain NTD from different novel coronavirus strains The sequences of subtype variants of the strain and other major variants enhance the immune response to various variants.

Benefits of technology

This recombinant chimeric antigen can significantly increase the level of neutralizing antibodies against different strains of the novel coronavirus, especially the Omicron variant and the Alpha, Beta and Delta variants that jointly contain key mutation sites, providing a relatively balanced and efficient protective effect. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060197A_ABST
    Figure CN119060197A_ABST
Patent Text Reader

Abstract

The invention relates to a novel coronavirus recombinant chimeric antigen as well as a preparation method and application thereof. The recombinant chimeric antigen comprises a receptor binding region RBD of a surface spike protein of a novel coronavirus strain or a functional active fragment thereof and an N-terminal structural domain NTD or a functional active fragment thereof, wherein the receptor binding region RBD or the functional active fragment thereof and the N-terminal domain NTD or the functional active fragment thereof are derived from different novel coronavirus strains, and at least one is derived from an Omicro variant. The recombinant chimeric antigen provided by the invention can more efficiently activate a broad-spectrum protective antibody, and can achieve a good prevention or treatment effect on D614G variants and various Omicron subtype variants.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biomedical engineering, and in particular relates to a recombinant chimeric antigen comprising a receptor binding domain (RBD) or a functionally active fragment thereof and an N-terminal domain (NTD) or a functionally active fragment thereof of an S protein derived from different novel coronavirus strains, a preparation method thereof, and its application in the field of immunotherapy and prevention. Background Art

[0002] Infection with the new coronavirus (SARS-CoV-2) can cause acute respiratory infectious diseases. The new coronavirus belongs to the genus Beta-coronavirus of the family Coronaviridae, has an envelope, and is a positive-strand RNA virus.

[0003] The receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S protein) is considered to be the most important antigenic target region for inducing the body to produce neutralizing antibodies. As a vaccine, RBD can focus the neutralizing antibodies stimulated by the body on receptor binding to the virus, which can improve the immunogenicity and immune efficiency of the vaccine. The N-terminal domain (NTD) of the SARS-CoV-2 spike protein (S protein) is a sequence at the N-terminus of the viral S protein, which can bind to the proteins or glycoproteins of the host cells and mediate the invasion of the virus into the host cells. Therefore, this region may contain epitopes that induce the production of neutralizing antibodies.

[0004] The novel coronavirus has a variety of mutant strains, among which the Omicron variant has as many as 37 mutation sites on the viral S protein, and has serious immune escape from the neutralizing antibody drugs and humoral immune responses activated by vaccines developed based on the novel coronavirus prototype strain. However, studies have reported that although the immune response activated by the vaccine developed with the Omicron sequence is stronger against the Omicron variant, the cross-reaction to the prototype strain and other strains is very weak, which is not suitable for the current coexistence of the prototype strain and multiple variants, and the epidemic variants are still changing rapidly. Therefore, it is necessary to develop a vaccine that has a strong protective effect against the current global epidemic strains and can induce a broad-spectrum immune response, which can play a vital role in the prevention and control of novel coronavirus infections. Summary of the invention

[0005] The purpose of the present invention is to provide a new coronavirus recombinant chimeric antigen, an immunogenic composition, a preparation method and an application thereof. The recombinant chimeric antigen according to the present invention is composed of a receptor binding region RBD or a functionally active fragment of a surface spike protein derived from at least one new coronavirus strain, and an N-terminal domain NTD or a functionally active fragment of a surface spike protein derived from another new coronavirus strain through an appropriate connection sequence or direct series connection. It can more efficiently activate broad-spectrum protective antibodies, especially for prototype strains, D614G variants and various current Omicron subtype variants. It can have a good preventive or therapeutic effect.

[0006] The technical solution of the present invention is as follows:

[0007] The first aspect of the present invention provides a recombinant chimeric antigen of the new coronavirus, comprising the receptor binding region RBD or a functionally active fragment thereof and the N-terminal domain NTD or a functionally active fragment thereof of the surface spike protein of the new coronavirus strain, wherein the receptor binding region RBD or a functionally active fragment thereof and the N-terminal domain NTD or a functionally active fragment thereof are derived from different new coronavirus strains, and at least one is derived from an Omicron variant.

[0008] In some embodiments, the Omicron variant includes at least one of the subtype variants BA.1, BA.1.1, BA.2, BA.2.12.1, BA.3, BA.4, BA.5, BQ.1.1, BF.7, XBB.1.5, XBB.1.16, EG.5 and JN.1, and the other strains are selected from at least one of the novel coronavirus prototype strain, Alpha variant, Beta variant, Gamma variant, Delta variant, Lambda variant, and Mu variant.

[0009] In some embodiments, the RBD or a functionally active fragment thereof is derived from at least one of the prototype strain, the Beta variant, the Delta variant, and the Omicron variant, and the NTD or a functionally active fragment thereof is derived from the Omicron variant.

[0010] In some embodiments, the recombinant chimeric antigen comprises a first amino acid sequence AB and a second amino acid sequence CD of the receptor binding region RBD or a functionally active fragment thereof of the surface spike protein of different novel coronavirus strains, wherein: CD is directly or indirectly chimeric in AB through a connecting sequence to form A-(CD) by replacing the amino acid residues in AB. n -B, n represents the number of amino acid sequence CD, n is an integer ≥ 1; preferably, n is an integer selected from 1-10; more preferably, it is an integer selected from 1-5.

[0011] In some embodiments, the recombinant chimeric antigen further comprises a third amino acid sequence EF of the receptor binding region RBD or a functionally active fragment thereof of the surface spike protein of different novel coronavirus strains, wherein: EF is directly or indirectly chimerized in AB through a connecting sequence to form A-(CD) by replacing the amino acid residues in AB n -(EF) m -B, m represents the number of amino acid sequences EF, m is an integer ≥ 1; preferably, m is an integer selected from 1-10; more preferably, it is an integer selected from 1-5.

[0012] In some embodiments, the number of amino acid residues in CD or EF is 10N60, for example, 10 amino acid residues, 15 amino acid residues, 20 amino acid residues, 25 amino acid residues, 30 amino acid residues, 35 amino acid residues, 40 amino acid residues, 45 amino acid residues, 50 amino acid residues, 55 amino acid residues or 60 amino acid residues.

[0013] In some embodiments, the RBD or its functionally active N-terminus is directly connected to the C-terminus of the NTD or its functionally active fragment or is connected via a linker sequence.

[0014] In some embodiments, the Omicron variant is selected from at least one of BQ.1.1, BF.7, XBB.1.5, XBB.1.16, EG.5 and JN.1.

[0015] In some preferred embodiments, the recombinant chimeric antigen further comprises a foldon domain or a functionally active fragment thereof.

[0016] In some embodiments, the N-terminus of the foldon domain or its functionally active fragment is directly connected to the C-terminus of the RBD or its functionally active fragment or is connected via a connecting sequence, and the N-terminus of the RBD or its functionally active fragment is directly connected to the C-terminus of the NTD or its functionally active fragment or is connected via a connecting sequence. In some preferred embodiments, the connecting sequence is GSGSG.

[0017] In some embodiments, the RBD or a functionally active fragment thereof of the recombinant chimeric antigen is derived from a BQ.1.1 subtype variant of an Omicron variant, and the NTD or a functionally active fragment thereof is derived from an XBB.1.5 subtype variant of an Omicron variant, and the recombinant chimeric antigen is NTD(XBB.1.5)-RBD(BQ.1.1). In the case where the recombinant chimeric antigen comprises a foldon domain or a functionally active fragment thereof, the recombinant chimeric antigen is NTD(XBB.1.5)-RBD(BQ.1.1)-foldon.

[0018] In some embodiments, the RBD or its functionally active fragment of the recombinant chimeric antigen is derived from the XBB.1.5 subtype variant of the Omicron variant, and the NTD or its functionally active fragment is derived from the BQ.1.1 subtype variant of the Omicron variant, and the recombinant chimeric antigen is NTD(BQ.1.1)-RBD(XBB.1.5). In the case where the recombinant chimeric antigen comprises a foldon domain or its functionally active fragment, the recombinant chimeric antigen is NTD(BQ.1.1)-RBD(XBB.1.5)-foldon.

[0019] In some embodiments, the RBD or a functionally active fragment thereof of the recombinant chimeric antigen is derived from an XBB.1.16 subtype variant of an Omicron variant, and the NTD or a functionally active fragment thereof is derived from an XBB.1.5 subtype variant of an Omicron variant, and the recombinant chimeric antigen is NTD(XBB.1.5)-RBD(XBB.1.16). In the case where the recombinant chimeric antigen comprises a foldon domain or a functionally active fragment thereof, the recombinant chimeric antigen is NTD(XBB.1.5)-RBD(XBB.1.16)-foldon.

[0020] In some embodiments, the RBD or a functionally active fragment thereof of the recombinant chimeric antigen is derived from an XBB.1.5 subtype variant of an Omicron variant, and the NTD or a functionally active fragment thereof is derived from an XBB.1.16 subtype variant of an Omicron variant, and the recombinant chimeric antigen is NTD(XBB.1.16)-RBD(XBB.1.5). In the case where the recombinant chimeric antigen comprises a foldon domain or a functionally active fragment thereof, the recombinant chimeric antigen is NTD(XBB.1.16)-RBD(XBB.1.5)-foldon.

[0021] In some embodiments, the RBD or its functionally active fragment of the recombinant chimeric antigen is derived from the BQ.1.1 subtype variant of the prototype strain and the Omicron variant, and the NTD or its functionally active fragment is derived from the XBB.1.5 subtype variant of the Omicron variant, and the recombinant chimeric antigen is NTD(XBB.1.5)-RBD(prototype strain-BQ.1.1). In the case where the recombinant chimeric antigen comprises a foldon domain or its functionally active fragment, the recombinant chimeric antigen is NTD(XBB.1.5)-RBD(prototype strain-BQ.1.1)-foldon.

[0022] In some embodiments, the RBD or its functionally active fragment of the recombinant chimeric antigen is derived from the XBB.1.5 subtype variant of the prototype strain and the Omicron variant, and the NTD or its functionally active fragment is derived from the BQ.1.1 subtype variant of the Omicron variant, and the recombinant chimeric antigen is NTD(BQ.1.1)-RBD(prototype strain-XBB.1.5). In the case where the recombinant chimeric antigen comprises a foldon domain or its functionally active fragment, the recombinant chimeric antigen is NTD(BQ.1.1)-RBD(prototype strain-XBB.1.5)-foldon.

[0023] In some embodiments, the RBD or its functionally active fragment of the recombinant chimeric antigen is derived from the BQ.1.1h and BF.7 subtype variants of the prototype strain and the Omicron variant, and the NTD or its functionally active fragment is derived from the XBB.1.5 subtype variant of the Omicron variant, and the recombinant chimeric antigen is NTD(XBB.1.5)-RBD(prototype strain-BQ.1.1-BF.7). In the case where the recombinant chimeric antigen comprises a foldon domain or its functionally active fragment, the recombinant chimeric antigen is NTD(XBB.1.5)-RBD(prototype strain-BQ.1.1-BF.7)-foldon.

[0024] In some embodiments, the RBD or its functionally active fragment of the recombinant chimeric antigen is derived from the XBB.1.5 and BF.7 subtype variants of the prototype strain and the Omicron variant, and the NTD or its functionally active fragment is derived from the BQ.1.1 subtype variant of the Omicron variant, and the recombinant chimeric antigen is NTD(BQ.1.1)-RBD(prototype strain-XBB.1.5-BF.7). In the case where the recombinant chimeric antigen comprises a foldon domain or its functionally active fragment, the recombinant chimeric antigen is NTD(BQ.1.1)-RBD(prototype strain-XBB.1.5-BF.7)-foldon.

[0025] Similarly, the recombinant chimeric antigen can also be NTD(XBB.1.5)-RBD(Delta-BQ.1.1), NTD(BQ.1.1)-RBD(Delta-XBB.1.5), NTD(XBB.1.5)-RBD(Delta-BQ.1.1-BF.7), NTD(BQ.1.1)-RBD(Delta-XBB.1.5-BF.7), NTD(BQ.1.1)-RBD(Delta-EG.5), NTD(BQ.1.1)-RBD(Delta-JN.1), etc. When the recombinant chimeric antigen contains a foldon domain or a functionally active fragment thereof, the recombinant chimeric antigen is NTD(XBB.1.5)-RBD(Delta-BQ.1.1)-foldon, NTD(BQ.1.1)-RBD(Delta-XBB.1.5)-foldon, NTD(XBB.1.5)-RBD(Delta-BQ.1.1-BF.7)-foldon, NTD(BQ.1.1)-RBD(Delta-XBB.1.5-BF.7)-foldon, NTD(BQ.1.1)-RBD(Delta-EG.5)-foldon, NTD(BQ.1.1)-RBD(Delta-JN.1)-foldon, etc.

[0026] In some specific embodiments, the recombinant chimeric antigen has an amino acid sequence shown in any one of SEQ ID NOs: 1-3.

[0027] The second aspect of the present invention provides a recombinant nucleic acid, which comprises a polynucleotide sequence encoding the recombinant chimeric antigen, wherein the polynucleotide is a codon-optimized nucleotide sequence and may be DNA, mRNA or circRNA. Preferably, the DNA sequence of the recombinant nucleic acid is as shown in any one of SEQ ID NOs: 6-8.

[0028] The third aspect of the present invention provides a nucleic acid construct, which comprises the recombinant nucleic acid as described in the second aspect above, and optionally, at least one expression control element operably linked to the recombinant nucleic acid.

[0029] The fourth aspect of the present invention provides an expression vector comprising the nucleic acid construct as described in the third aspect above.

[0030] The fifth aspect of the present invention provides a host cell, which comprises the nucleic acid encoding the recombinant chimeric antigen as described in the second aspect, the nucleic acid construct as described in the third aspect, or the expression vector as described in the fourth aspect; the host cell includes a mammalian cell, an insect cell, a yeast cell or a bacterial cell; optionally, the mammalian cell includes a HEK293T cell, a HEK293F cell, an Expi293F cell or a CHO cell; optionally, the bacterial cell includes an Escherichia coli cell.

[0031] The sixth aspect of the present invention provides a method for preparing the recombinant chimeric antigen as described in the first aspect, comprising the following steps:

[0032] (1) constructing a recombinant expression plasmid using the nucleotide sequence encoding the novel coronavirus recombinant chimeric antigen;

[0033] (2) Transforming the constructed recombinant expression plasmid into a host bacterium and screening the correct recombinant expression plasmid;

[0034] (3) transfecting mammalian host cells with the screened recombinant expression plasmid for expression;

[0035] (4) Collecting the cell culture supernatant and purifying it to obtain the recombinant chimeric antigen.

[0036] The seventh aspect of the present invention provides an immunogenic composition, which comprises the recombinant chimeric antigen as described in the first aspect, the recombinant nucleic acid as described in the second aspect, the nucleic acid construct as described in the third aspect, the expression vector as described in the fourth aspect, or the host cell as described in the fifth aspect.

[0037] In some embodiments, the immunogenic composition comprises a first component, wherein the first component comprises NTD or a functionally active fragment thereof derived from the XBB.1.5 variant and RBD or a functionally active fragment thereof derived from the prototype strain, i.e., NTD(XBB.1.5)-RBD(prototype strain); and a second component, wherein the second component comprises NTD or a functionally active fragment thereof derived from the BQ.1.1 variant and RBD or a functionally active fragment thereof derived from the Delta variant, i.e., NTD(BQ.1.1)-RBD(Delta). In a preferred embodiment, each component further comprises a foldon domain or a functionally active fragment thereof, i.e., the immunogenic composition comprises two components, NTD(XBB.1.5)-RBD(prototype strain)-foldon and NTD(BQ.1.1)-RBD(Delta)-foldon.

[0038] In some embodiments, the immunogenic composition comprises a first component, wherein the first component comprises NTD or a functionally active fragment thereof derived from the XBB.1.5 variant and RBD or a functionally active fragment thereof derived from the prototype strain, i.e., NTD(XBB.1.5)-RBD(prototype strain); and a second component, wherein the second component comprises NTD or a functionally active fragment thereof derived from the XBB.1.16 variant and RBD or a functionally active fragment thereof derived from the Delta variant, i.e., NTD(XBB.1.16)-RBD(Delta). In a preferred embodiment, each component further comprises a foldon domain or a functionally active fragment thereof, i.e., the immunogenic composition comprises two components, NTD(XBB.1.5)-RBD(prototype strain)-foldon and NTD(XBB.1.16)-RBD(Delta)-foldon.

[0039] Similarly, the immunogenic composition may comprise at least one component selected from NTD(XBB.1.5)-RBD(prototype strain-BF.7), NTD(XBB.1.5)-RBD(Delta-BF.7), NTD(BQ.1.1)-RBD(Delta-XBB.1.5), NTD(XBB.1.16)-RBD(Delta-BF.7), NTD(XBB.1.5)-RBD(prototype strain-XBB.1.16), NTD(XBB.1.5)-RBD(Delta-XBB.1.16), etc. In a preferred embodiment, each component also contains a foldon domain or a functionally active fragment thereof, that is, each component can be NTD(XBB.1.5)-RBD(prototype strain-BF.7)-foldon, NTD(XBB.1.5)-RBD(Delta-BF.7)-foldon, NTD(BQ.1.1)-RBD(Delta-XBB.1.5)-foldon, NTD(XBB.1.16)-RBD(Delta-BF.7)-foldon, NTD(XBB.1.5)-RBD(prototype strain-XBB.1.16)-foldon, NTD(XBB.1.5)-RBD(Delta-XBB.1.16)-foldon, etc. In some embodiments, the immunogenic composition may also contain NTD or a functionally active fragment thereof and RBD or a functionally active fragment thereof derived from the same strain, such as NTD(prototype strain)-RBD(prototype strain), NTD(Delta)-RBD(Delta), NTD(prototype strain)-RBD(prototype strain)-foldon, NTD(Delta)-RBD(Delta)-foldon, etc.

[0040] The eighth aspect of the present invention provides a new coronavirus recombinant protein vaccine, which includes the recombinant chimeric antigen as described in the first aspect above, or the immunogenic composition as described in the seventh aspect above, and an adjuvant; the adjuvant is selected from one or any combination of aluminum adjuvant, lipopolysaccharide, saponin, PolyI:C, CpG and emulsion adjuvant.

[0041] In some embodiments, the aluminum adjuvant is selected from aluminum hydroxide and aluminum phosphate.

[0042] In some embodiments, the saponin is selected from QS-7, QS-17, QS-18, QS21, TQL-1055, etc. In a preferred embodiment, the saponin is selected from QS21 or TQL-1055.

[0043] In some embodiments, the adjuvant is a liposomal adjuvant or an emulsion adjuvant comprising saponin.

[0044] In some embodiments, the human dose of adjuvant comprises QS21 in an amount of 5-50 μg, for example, 6 μg, 7 μg, 8 μg, 9 μg, 10 μg, 11 μg, 12 μg, 13 μg, 14 μg, 15 μg, 16 μg, 17 μg, 18 μg, 19 μg, 20 μg, 21 μg, 22 μg, 23 μg, 24 μg, 25 μg, 26 μg, 27 μg, 28 μg, 29 μg, 30 μg, 31 μg, 32 μg, 33 μg, 34 μg, 35 μg, 36 μg, 37 μg, 38 μg, 39 μg, 40 μg, 41 μg, 42 μg, 43 μg, 5μg, 26μg, 27μg, 28μg, 29μg, 30μg, 31μg, 32μg, 33μg, 34μg, 35βg, 36μg, 37μg, 38μg, 39μg, 40μg, 41μg, 42μg, 43μg, 44μg, 44μg, 45μg, 46μg, 47μg, 48μg or 49μg.

[0045] In some embodiments, the lipopolysaccharide comprises Gram-negative bacterial lipopolysaccharide LPS, glucopyranosyl lipid A (GLA), and MPL (3D-MPL).

[0046] In some embodiments, the human dose of adjuvant comprises MPL in an amount of 1-50 μg, for example 2 μg, 3 μg, 4 μg, 5 μg, 6 μg, 7 μg, 8 μg, 9 μg, 10 μg, 11 μg, 12 μg, 13 μg, 14 μg, 15 μg, 16 μg, 17 μg, 18 μg, 19 μg, 20 μg, 21 μg, 22 μg, 23 μg. , 24μg, 25μg, 26μg, 27μg, 28μg, 29μg, 30μg, 31μg, 32μg, 33μg, 34μg, 35μg, 36μg, 37 μg, 38μg, 39μg, 40μg, 41μg, 42μg, 43μg, 44μg, 44μg, 45μg, 46μg, 47μg, 48μg or 49μg.

[0047] In some embodiments, the saponin-containing liposomal adjuvant specifically contains QS21 and MPL.

[0048] In some embodiments, a human dose of the immunogenic composition comprises 25 μg MPL and 25 μg QS21. In other embodiments, a human dose of the immunogenic composition comprises 10 μg MPL and 10 μg QS21.

[0049] In some embodiments, the liposomes contain a neutral lipid, such as phosphatidylcholine, which can be selected from, for example, egg yolk phosphatidylcholine, dioleoylphosphatidylcholine (DOPC), or dilauroylphosphatidylcholine.

[0050] In some embodiments, the liposomes contain a sterol, suitable sterols include p-sitosterol, stigmasterol, ergosterol, ergocalciferol and cholesterol. In a preferred embodiment, the adjuvant composition comprises cholesterol as the sterol.

[0051] In some embodiments, the saponin-containing liposomal adjuvant comprises TQL-1055 and MPL.

[0052] In a preferred embodiment, the adjuvant composition of AS01 for human use is PBS buffer containing 50 μg MPL, 50 μg QS21, 1 mg DOPC and 0.25 mg cholesterol per 0.5 ml.

[0053] In some embodiments, the emulsion contains an oil phase and an aqueous phase.

[0054] In some embodiments, the oil phase comprises a metabolizable oil, preferably, the metabolizable oil is squalene.

[0055] In some embodiments, the oil phase further comprises α-tocopherol.

[0056] In some embodiments, the weight ratio of squalene to α-tocopherol is 0.8-1, such as 0.85-0.95, preferably 0.9, and the AS03 emulsion composition for human use contains 4.86 mg polysorbate 80 (Tween 80), 10.69 mg squalene and 11.86 mg α-tocopherol per 0.5 ml.

[0057] In some embodiments, the oil phase further comprises Span 85. Preferably, the oil-in-water emulsion is MF59, comprising 1% squalene, 0.5% Tween 80 and 0.5% Span 85.

[0058] In some embodiments, the weight ratio of squalene to Span 85 is 8-10, preferably 8.4.

[0059] In some embodiments, the saponin-containing emulsion adjuvant comprises QS21 and MPL.

[0060] In some embodiments, the emulsion adjuvant comprises squalene, tocopherol, and Tween 80.

[0061] In some embodiments, the emulsion adjuvant is an oil-in-water emulsion comprising squalene, Span 85, and Tween 80.

[0062] In some embodiments, the adjuvant comprises an aluminum adjuvant and 3D-MPL.

[0063] In some embodiments, the adjuvant comprises an emulsion and nano-aluminum particles uniformly dispersed in the emulsion.

[0064] In some embodiments, the emulsion comprises squalene, tocopherol, Tween 80, and Span 85.

[0065] In some embodiments, the adjuvant comprises Poly I:C and 3D-MPL.

[0066] The ninth aspect of the present invention provides a new coronavirus recombinant nucleic acid vaccine, which comprises the recombinant nucleic acid described in the second aspect.

[0067] In some embodiments, the recombinant nucleic acid vaccine is a DNA vaccine, which comprises a eukaryotic expression vector and a DNA sequence encoding the recombinant chimeric antigen as described in the first aspect above, which is constructed into the eukaryotic expression vector; optionally, the eukaryotic expression vector is selected from the pGX0001, pVAX1, pCAGGS and pCDNA series vectors.

[0068] In some embodiments, the recombinant nucleic acid vaccine is an mRNA vaccine, which comprises an mRNA sequence encoding the recombinant chimeric antigen as described in the first aspect above and lipid nanoparticles (LNP), wherein the mRNA is encapsulated in the lipid nanoparticles (LNP).

[0069] In some embodiments, the recombinant nucleic acid vaccine is a circRNA vaccine, which comprises a circular RNA sequence encoding the recombinant chimeric antigen as described in the first aspect above.

[0070] The tenth aspect of the present invention provides a recombinant chimeric antigen as described in the first aspect, the recombinant nucleic acid as described in the second aspect, the nucleic acid construct as described in the third aspect, the expression vector as described in the fourth aspect, the host cell as described in the fifth aspect, the immunogenic composition as described in the seventh aspect, the new coronavirus recombinant protein vaccine as described in the eighth aspect, and the new coronavirus recombinant nucleic acid vaccine as described in the ninth aspect for use in the preparation of a medicament for preventing new coronavirus infection.

[0071] Compared with the prior art, the present invention has the following beneficial effects:

[0072] The present invention screened out NTD sequences and RBD sequences with immune advantages, and the corresponding recombinant chimeric antigens have strong and broad-spectrum immunogenicity, which can provide a relatively balanced and efficient protection against different strains of the new coronavirus, especially various Omicron variants, and even Alpha, Beta and Delta variants that share the key mutation site D614G. BRIEF DESCRIPTION OF THE DRAWINGS

[0073] The following drawings are intended only to illustrate and explain the present invention, and are not intended to limit the scope of the present invention.

[0074] Figure 1 is the absorbance curve of the NTD (BQ.1.1) -RBD (XBB.1.5) -foldon recombinant chimeric protein purified by HPLC-SEC as described in Example 2 of the present invention, as well as the SDS-PAGE and WB identification results of the collected elution peaks.

[0075] Figure 2 is the absorbance curve of the NTD (XBB.1.5) -RBD (prototype strain - BQ.1.1 -BF.7) -foldon recombinant chimeric protein purified by HPLC-SEC as recorded in Example 2 of the present invention, as well as the SDS-PAGE and WB identification results of the collected elution peaks.

[0076] Figure 3 is the absorbance curve of the NTD (BQ.1.1) -RBD (prototype strain - XBB.1.5-BF.7) -foldon recombinant chimeric protein purified by HPLC-SEC as recorded in Example 2 of the present invention, as well as the SDS-PAGE and WB identification results of the collected elution peaks.

[0077] Figure 4 is the absorbance curve of the NTD(BQ.1.1)-RBD(BQ.1.1)-foldon recombinant chimeric protein purified by HPLC-SEC as described in Example 2 of the present invention, as well as the SDS-PAGE and WB identification results of the collected elution peaks.

[0078] Figure 5 is the absorbance curve of the NTD(XBB.1.5)-RBD(XBB.1.5)-foldon recombinant chimeric protein purified by HPLC-SEC as described in Example 2 of the present invention, as well as the SDS-PAGE and WB identification results of the collected elution peaks.

[0079] Figure 6 As recorded in Example 5 of the present invention, the neutralizing antibody titer results of the serum collected from mice 14 days after the second immunization with the immunogen against pseudoviruses of various variants of the new coronavirus.

[0080] Figure 7 As recorded in Example 6 of the present invention, the neutralizing antibody titer results of the serum collected from mice 14 days after the first immunization with the bivalent vaccine against pseudoviruses of various variants of the new coronavirus. DETAILED DESCRIPTION

[0081] The present invention will be further described below by non-limiting examples, and it is well known to those skilled in the art that many modifications may be made to the present invention without departing from the spirit of the present invention, and such modifications also fall within the scope of the present invention. The following examples are only intended to illustrate the present invention and should not be considered to limit the scope of the present invention, because the embodiments are necessarily diverse. The terms used in this specification are only intended to illustrate specific embodiments, and not as a limitation, and the scope of the present invention is defined in the appended claims.

[0082] Unless otherwise specified, all technical and scientific terms used in this specification have the same meaning as those generally understood by those skilled in the art to which this invention belongs. The preferred methods and materials of the present invention are described below, but any methods and materials similar or equivalent to those described in this specification can be used to implement or test the present invention. The following experimental methods are conventional methods or methods described in product specifications unless otherwise specified, and the experimental materials used can be easily obtained from commercial companies unless otherwise specified.

[0083] Definition of terms

[0084] In the present application, when "one embodiment" is mentioned, it means that the specific parameters, steps, etc. described in the embodiment are at least included in one embodiment of the present invention. Therefore, in the present application, if terms such as "according to one embodiment of the present invention" or "in one embodiment" are used, they are not used to specifically refer to the same embodiment, and if terms such as "in another embodiment", "according to different embodiments of the present invention", or "according to another embodiment of the present invention" are used, they are not used to specifically refer to that the mentioned features can only be included in specific different embodiments. It should be understood by those skilled in the art that the specific parameters, steps, etc. disclosed in one or more embodiments of the present specification can be combined in any suitable manner.

[0085] In the present application, the term "foldon domain" generally refers to the residues at the C-terminus of the phage T4 fiber protein. In the present application, the foldon domain can be the 27 residues or mutants at the C-terminus of the phage T4 fiber protein. In the present application, the foldon domain can be a truncation or an extension obtained by truncating the 27 residues at the C-terminus of the phage T4 fiber protein or adding 1, 2, 3, 4, 5, or 6 or 10 amino acids at the N-terminus or C-terminus. In the present application, "mutant" generally refers to a sequence that is different from a reference sequence because it contains one or more differences (mutations). The difference can be a substitution, deletion or insertion of one or more amino acids.

[0086] In this application, the term "adjuvant" refers to a substance that has the function of enhancing immune response and can be clinically applied to humans or has the prospect of being applied to humans, including various adjuvants that are currently approved and may be approved in the future, such as but not limited to aluminum adjuvants and various forms of adjuvant compositions.

[0087] In this application, the term "include" generally means to include, encompass, contain or encompass. In some cases, it also means "for", "consisting of...".

[0088] Example 1. Construction of recombinant expression plasmid

[0089] The construct shown in Table 1 was designed by directly concatenating the NTD sequence and RBD sequence / RBD chimeric sequence derived from different strains, connecting a signal peptide (as shown in SEQ ID NO: 11) to the N-terminus, connecting a foldon domain (as shown in SEQ ID NO: 12) to the C-terminus through a connecting sequence, and finally adding 6 histidine tags (HHHHHH) to the C-terminus of the foldon domain to obtain the construct shown in Table 1.

[0090] Table 1 Construction scheme of each construct

[0091] Amino acid sequence Recombinant expression plasmid DNA sequence SEQ ID NO: 1 NTD(BQ.1.1)-RBD(XBB.1.5)-foldon-6*His SEQ ID NO: 6 SEQ ID NO: 2 NTD(XBB.1.5)-RBD(prototype strain-BQ.1.1-BF.7)-foldon-6*His SEQ ID NO: 7 SEQ ID NO: 3 NTD(BQ.1.1)-RBD(prototype strain-XBB.1.5-BF.7)-foldon-6*his SEQ ID NO: 8 SEQ ID NO: 4 NTD(BQ.1.1)-RBD(BQ.1.1)-foldon-6*His SEQ ID NO: 9 SEQ ID NO: 5 NTD(XBB.1.5)-RBD(XBB.1.5)-foldon-6*His SEQ ID NO: 10

[0092] The amino acid sequence of the above construct was codon optimized according to the host CHO cells.

[0093] Fragment cloning: The primers of each construct were amplified by PCR to obtain fragment PCR products, which were recombined into the target vector pcDNA3.1(+) (BamHI-XhoI restriction vector) by multi-segment recombination to obtain each recombinant expression plasmid. The reaction system is shown in Table 2, and the connection solution was connected at a constant temperature of 52°C for 30 minutes.

[0094] Table 2 The reaction system of the treated target fragment and the vector ligation

[0095] name volume Vector after enzyme digestion 5μl Purified PCR products 5μl Seamless assembly MIX 10μl Total volume 20μl

[0096] Conversion: Pipette 1-3 μl of each recombinant expression plasmid described in Example 1 at a concentration of 100 ng / μl into 100 μl of competent cells, gently shake and rotate to mix, and place on ice for 3 minutes; place in a 42°C water bath for 90 s without shaking; place in an ice bath for about 3 minutes; add 500-800 μl of LB medium pre-warmed at 37°C to each tube, and gently shake at 200 rpm at 37°C for 40 minutes.

[0097] Verification of recombinant expression plasmid: Prepare agar plates containing corresponding resistance; take 100 μl of bacterial solution and spread it on the agar plate containing corresponding resistance, use a sterile glass applicator to gently spread the bacteria on the surface of the plate, and place the plate at 37℃ for 15 minutes; invert the plate and culture it at 37℃ for 12-16 hours to see colonies; pick bacteria on the plate, shake the bacteria at 37℃, 250r / min for 14 hours, use the bacterial solution for PCR identification, and send the positive clone bacterial solution for sequencing. The plasmid with correct sequencing alignment is double-digested with BamHI-XhoI to obtain the target fragment.

[0098] Recombinant expression plasmid extraction: Inoculate 1% of E. coli cells (Stbl3) containing each recombinant expression plasmid in 2 ml of LB medium and culture overnight at 37°C with shaking. After treating the cells, extract 100 μg of plasmid using a plasmid extraction kit. Sequence the correct plasmid and perform double restriction digestion with BamHI-XhoI to obtain the target fragment.

[0099] Example 2. Cell transfection and protein purification

[0100] Cell transfection: The obtained plasmid was introduced into CHO cells by transient transfection. After culture, the protein was collected and purified. CHO cells were subcultured and expanded using ExpiCHO Expression Medium (EXPICHO from Thermo). During all cell manipulations, the host cells were gently rotated to mix; vigorous mixing / pipetting was avoided. Subculture and expand CHO cells until the cell density reached 4×10 6 ~6×10 6 Day -1: Cell expansion, expand the cultured cells to 3×10 6 N4×10 6 Day 0: Transfect cells and measure viable cell density and viability. The cell density should reach 7 × 10 6 ~10×10 6 / mL, and the survival rate reaches 95-99% for transfection. Fresh cell expression medium is preheated to 37°C and the cells are diluted to a final density of 6×106 / mL, cultured in a 50mm amplitude incubator at 90rpm, 37℃, 8% CO2. Use OPti-PRO SFM medium to prepare transfection reagent and recombinant expression plasmid complex (4℃), for example: prepare 40μl OPti-PRO SFM for 1ml cells, add 0.8μg of the corresponding recombinant expression plasmid, mix and place for 5min; prepare 40μl OPti-PRO SFM, add 3μl Expi Fectamine CHO reagent, mix and place for 5min, at room temperature for 1-5 minutes, then slowly transfer the solution to a shake flask and shake, gently shake the shaker during the addition process. Culture the cells in a 50mm amplitude incubator at 90rpm, 37℃, 8% CO2. 18-22 hours after transfection, add Enhancer and ExpiCHO Feed, and perform the standard experimental protocol, for example: add 6μl Enhancer and 0.24ml ExpiCHO Feed to 1ml cells, and culture the cells in a 50mm amplitude incubator at 90rpm at 37℃, 8% CO2. The proteins were collected 8 days after transfection and purified by HPLC-SEC to obtain a trimer protein with a purity of ≥ 95%, which was the desired recombinant chimeric purified protein.

[0101] The obtained recombinant chimeric purified protein was verified by SDS-PAGE and Western Blot, and the results are shown in Figures 1 to 5.

[0102] Example 3. Preparation of recombinant protein vaccine

[0103] Each recombinant chimeric purified protein obtained in Example 2 was diluted to 80 μg / ml with a diluent (1×PBS buffer) and fully mixed with an equal volume of AS03 adjuvant to prepare an immune sample, wherein the adjuvant composition includes 10.69 mg of squalene, 11.86 mg of α-tocopherol, 4.86 mg of polysorbate 80, 3.53 mg of sodium chloride, 0.09 mg of potassium chloride, 0.51 mg of disodium hydrogen phosphate, 0.09 mg of potassium dihydrogen phosphate and water for injection per 0.5 ml.

[0104] Example 4. Construction of pseudovirus

[0105] China Science and Technology Guobang (Beijing) Inspection and Testing Co., Ltd. was commissioned to construct pseudoviruses of D614G, Omicron-BQ.1.1 and Omicron-XBB.1.5, and to conduct corresponding tests in preparation for subsequent in vitro neutralization tests.

[0106] Example 5. Evaluation of vaccine immunogenicity

[0107] BALB / c mice (female, 6-8 weeks old, purchased from the Institute of Laboratory Animals, Chinese Academy of Medical Sciences) were used for group immunization and randomly divided into 5 groups, with 5 mice in each group. They first received basic immunization (2 injections of inactivated vaccine, 21 days apart). The first booster immunization was performed 10 months after the basic immunization, and blood was collected for testing 14 days later. The second booster immunization was performed 21 days after the first booster immunization, and blood was collected for testing 14 days later. During the booster immunization, each mouse was injected intramuscularly with 100 μl of the immune sample (containing 4 μg antigen and 1 / 10 human dose AS03 adjuvant immunization). The collected blood samples were placed at 37°C for 1 hour, 4°C for 1 hour, centrifuged at 8000r / min for 10 minutes, and the serum was collected and stored at -20°C. The mouse grouping and immunization dose are shown in Table 3.

[0108] Table 3 Grouping and dosage of mice immunized with the novel coronavirus recombinant chimeric protein vaccine

[0109]

[0110] Using the novel coronavirus pseudovirus constructed in Example 4, the 50% pseudovirus neutralization titer of the collected immune mouse sera against the pseudovirus of each variant strain of the novel coronavirus was tested, including the D614G, Omicron-BQ.1.1 and Omicron-XBB.1.5 variants.

[0111] The method for detecting the neutralizing antibody titer of the new coronavirus pseudovirus (hereinafter referred to as pseudovirus) is as follows: In a 96-well plate, the immune mouse serum is diluted in a 2-fold gradient ratio, and then mixed with the pseudovirus respectively, and incubated at 37°C for 1 hour. The immune serum-pseudovirus mixture is transferred to a 96-well plate filled with Vero cells. After 15 hours, the positive cell value is calculated by CQ1 confocal cell imager (Yokogawa), and then the fitting curve is drawn in GraphPad Prism software to calculate the reciprocal of the serum dilution corresponding to 50% neutralization, which is the 50% pseudovirus neutralization titer. The pseudovirus neutralizing antibody titer test results are as follows Figure 6 As shown (Groups 1-5 from left to right).

[0112] The results showed that for the D614G strain, the neutralizing antibody titers GMT stimulated by NTD(BQ.1.1)-RBD(XBB.1.5)-foldon (Group 1), NTD(XBB.1.5)-RBD(prototype strain-BQ.1.1-BF.7)-foldon (Group 2) and NTD(BQ.1.1)-RBD(prototype strain-XBB.1.5-BF.7)-foldon (Group 3) were 12265, 44723 and 18627, respectively, which were significantly higher than 7791 and 2233 of the non-chimeric antigens NTD(BQ.1.1)-RBD(BQ.1.1)-foldon (Group 4) and NTD(XBB.1.5)-RBD(XBB.1.5)-foldon (Group 5), indicating that the chimeric antigens of the present invention can significantly improve the level of neutralizing antibodies against the D614G strain.

[0113] For the BQ.1.1 strain, the neutralizing antibody titer GMT stimulated by NTD(BQ.1.1)-RBD(BQ.1.1)-foldon (Group 4) was the highest (reaching 39074), which was as expected. The neutralizing antibody titer GMT levels stimulated by the chimeric antigens NTD(BQ.1.1)-RBD(XBB.1.5)-foldon (Group 1) and NTD(BQ.1.1)-RBD(prototype strain-XBB.1.5-BF.7)-foldon (Group 3) were also high, at 11355 and 7826, respectively, which were higher than those of the non-chimeric antigen NTD(XBB.1.5)-RBD(XBB.1.5)-foldon (Group 5) and the chimeric antigen NTD(XBB.1.5)-RBD(prototype strain-BQ.1.1-BF.7)-foldon (Group 2).

[0114] For the XBB.1.5 strain, unexpectedly, the neutralizing antibody titer GMT stimulated by NTD(BQ.1.1)-RBD(XBB.1.5)-foldon (Group 1) was the highest (reaching 15728), even higher than 7737 of NTD(XBB.1.5)-RBD(XBB.1.5)-foldon (Group 5). The neutralizing antibody titer GMT stimulated by NTD(XBB.1.5)-RBD(prototype strain-BQ.1.1-BF.7)-foldon (Group 2) and NTD(BQ.1.1)-RBD(BQ.1.1)-foldon (Group 4) were 2906 and 1973, respectively, and the neutralizing antibody titer GMT stimulated by NTD(BQ.1.1)-RBD(prototype strain-XBB.1.5-BF.7)-foldon (Group 3) was the lowest, only 610.

[0115] In summary, the neutralizing antibody titer GMT against the two strains D614G and XBB.1.5 stimulated by the chimeric antigen NTD (BQ.1.1) -RBD (XBB.1.5) -foldon (Group 1) of the present invention is greater than that of the non-chimeric antigen NTD (BQ.1.1) -RBD (BQ.1.1) -foldon (Group 4), and the neutralizing antibody titer GMT against the three strains D614G, BQ.1.1 and XBB.1.5 is greater than that of the non-chimeric antigen NTD (XBB.1.5) -RBD (XBB.1.1) -foldon (Group 4). 5)-foldon (Group 5); the neutralizing antibody titer GMT against the two strains D614G and XBB.1.5 stimulated by the chimeric antigen NTD (XBB.1.5)-RBD (prototype strain-BQ.1.1-BF.7)-foldon (Group 2) of the present invention was greater than that of the non-chimeric antigen NTD (BQ.1.1)-RBD (BQ.1.1)-foldon (Group 4), and the neutralizing antibody titer GMT against the D614G strain was greater than that of the non-chimeric antigen NTD (XBB.1.5)-RBD (XBB. 1.5)-foldon (Group 5); the neutralizing antibody titer GMT stimulated by the chimeric antigen NTD (BQ.1.1)-RBD (prototype strain-XBB.1.5-BF.7)-foldon (Group 3) of the present invention against one strain of D614G was greater than that of the non-chimeric antigen NTD (BQ.1.1)-RBD (BQ.1.1)-foldon (Group 4), and the neutralizing antibody titer GMT against both D614G and BQ.1.1 strains was greater than that of the non-chimeric antigen NTD (XBB.1.5 )-RBD(XBB.1.5)-foldon (Group 5), especially the neutralizing antibody titer GMT against the D614G strain stimulated by the chimeric antigen of the present invention is greater than that of the non-chimeric antigen, which indicates that the chimeric antigen of the present invention can provide a relatively balanced and efficient protection against different strains of the new coronavirus, especially various Omicron variants (such as BQ.1.1, XBB.1.5, XBB.1.16, etc.), and even Alpha, Beta and Delta variants that share the key mutation site D614G.

[0116] Example 6. Evaluation of the immunogenicity of a bivalent vaccine

[0117] BALB / c mice (female, 6-8 weeks old, purchased from the Institute of Laboratory Animals, Chinese Academy of Medical Sciences) were used for group immunization and randomly divided into 5 groups, 5 mice in each group, and first received basic immunization (2 injections of inactivated vaccine, 21 days apart). The first booster immunization was performed 10 months after the basic immunization, and blood was collected for testing 14 days later. During the booster immunization, 100 μl of immune sample (containing 4 μg antigen and 1 / 10 human dose AS03 adjuvant immunization) was injected intramuscularly into each mouse. The collected blood samples were placed at 37°C for 1 hour, 4°C for 1 hour, centrifuged at 8000r / min for 10 minutes, and serum was collected and stored at -20°C. The mouse grouping and immunization dose are shown in Table 4.

[0118] Table 4 Grouping and dosage of mice immunized with the novel coronavirus recombinant chimeric protein vaccine

[0119]

[0120] Using the novel coronavirus pseudovirus constructed in Example 4, the 50% pseudovirus neutralization titer of the collected immune mouse sera against the novel coronavirus Omicron-XBB.1.5 variant pseudovirus was tested.

[0121] The results of the pseudovirus neutralizing antibody titer test are as follows Figure 7 As shown (Groups 1-6 from left to right). The results showed that NTD(BQ.1.1)-RBD(XBB.1.5)-foldon (Group 3) and NTD(XBB.1.5)-RBD(BQ.1.1)-foldon (Group 4) had higher neutralizing antibody titers GMT against the Omicron-XBB.1.5 variant, which were 820 and 541, respectively. We speculate that due to the higher immunogenicity of the RBD component, when the RBD is derived from the XBB.1.5 variant (ie, NTD(BQ.1.1)-RBD(XBB.1.5)-foldon), the corresponding neutralizing antibody titer GMT is greater than that of the immunogen in which the RBD is derived from the BQ.1.1 variant (ie, NTD(XBB.1.5)-RBD(BQ.1.1)-foldon).

[0122] The neutralizing antibody titers of NTD(BA.2)-RBD(prototype strain)-foldon(Group 5) and NTD(prototype strain)-RBD(prototype strain)-foldon(Group 6) against the Omicron-XBB.1.5 variant were low, only 139 and 190, respectively. This should be due to the fact that there was no component derived from the Omicron-XBB.1.5 variant in the immunogen. On this basis, NTD(BQ.1.1)-RBD(XBB.1.5)-foldon was added. n, the neutralizing antibody titers GMT of the bivalent vaccines NTD(BQ.1.1)-RBD(XBB.1.5)-foldon+NTD(prototype strain)-RBD(prototype strain)-foldon (Group 1) and NTD(BQ.1.1)-RBD(XBB.1.5)-foldon+NTD(BA.2)-RBD(prototype strain)-foldon (Group 2) against the Omicron-XBB.1.5 variant strain were increased to 364 and 270, respectively.

[0123] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A recombinant chimeric antigen of the new coronavirus, comprising the receptor binding region RBD or a functionally active fragment thereof and the N-terminal domain NTD or a functionally active fragment thereof of the surface spike protein of the new coronavirus strain, wherein the receptor binding region RBD or a functionally active fragment thereof and the N-terminal domain NTD or a functionally active fragment thereof are derived from different new coronavirus strains, and at least one is derived from an Omicron variant.

2. The recombinant chimeric antigen according to claim 1, characterized in that The Omicron variants include at least one of the subtype variants BA.1, BA.1.1, BA.2, BA.2.12.1, BA.3, BA.4, BA.5, BQ.1.1, BF.7, XBB.1.5, XBB.1.16, EG.5 and JN.1, and the remaining strains are selected from at least one of the novel coronavirus prototype strain, Alpha variant, Beta variant, Gamma variant, Delta variant, Lambda variant and Mu variant.

3. The recombinant chimeric antigen according to claim 1, characterized in that The RBD or a functionally active fragment thereof is derived from at least one of the prototype strain, the Beta variant, the Delta variant and the Omicron variant, and the NTD or a functionally active fragment thereof is derived from the Omicron variant.

4. The recombinant chimeric antigen according to claim 3, characterized in that The recombinant chimeric antigen comprises a first amino acid sequence AB and a second amino acid sequence CD of the receptor binding region RBD or a functionally active fragment thereof of the surface spike protein of different novel coronavirus strains, wherein: CD is directly or indirectly chimeric in AB through a connecting sequence to form A-(CD) by replacing the amino acid residues in AB. n -B, the number of amino acid residues in CD is 10 to 60, n represents the number of amino acid sequence CD, and n is an integer ≥ 1; preferably, n is an integer selected from 1-10, and more preferably an integer selected from 1-5.

5. The recombinant chimeric antigen according to claim 4, characterized in that The recombinant chimeric antigen also includes a third amino acid sequence EF of the receptor binding region RBD or a functionally active fragment thereof derived from the surface spike protein of different novel coronavirus strains, wherein: EF is directly or indirectly chimerized in AB to form A-(CD) by replacing the amino acid residues in AB n -(EF) m -B, the number of amino acid residues in EF is 10 to 60, m represents the number of amino acid sequence EF, and m is an integer ≥ 1; preferably, m is an integer selected from 1-10; more preferably, it is an integer selected from 1-5.

6. The recombinant chimeric antigen according to claim 4 or 5, characterized in that The Omicron variant is selected from at least one of BQ.1.1, BF.7, XBB.1.5, XBB.1.16, EG.5 and JN.

1.

7. The recombinant chimeric antigen according to any one of claims 1 to 6, characterized in that: The recombinant chimeric antigen also comprises a foldon domain or a functionally active fragment thereof.

8. The recombinant chimeric antigen according to claim 7, characterized in that The N-terminus of the foldon domain or its functionally active fragment is directly connected to the C-terminus of the RBD or its functionally active fragment or is connected through a connecting sequence, and the N-terminus of the RBD or its functionally active fragment is directly connected to the C-terminus of the NTD or its functionally active fragment or is connected through a connecting sequence.

9. The recombinant chimeric antigen according to claim 8, characterized in that The recombinant chimeric antigen has an amino acid sequence shown in any one of SEQ ID NOs: 1-3. 10 . A recombinant nucleic acid comprising a polynucleotide sequence encoding the recombinant chimeric antigen according to claim 1 , wherein the polynucleotide is DNA, mRNA or circRNA.

11. A host cell carrying the recombinant nucleic acid of claim 10, wherein the host cell comprises a mammalian cell, an insect cell, a yeast cell or a bacterial cell; optionally, the mammalian cell comprises a HEK293T cell, a HEK293F cell, an Expi293F cell or a CHO cell; optionally, the bacterial cell comprises an Escherichia coli cell.

12. A method for preparing the recombinant chimeric antigen according to any one of claims 1 to 9, comprising the following steps: (1) constructing a recombinant expression plasmid using the nucleotide sequence encoding the novel coronavirus recombinant chimeric antigen; (2) Transforming the constructed recombinant expression plasmid into a host bacterium and screening the correct recombinant expression plasmid; (3) transfecting mammalian host cells with the screened recombinant expression plasmid for expression; (4) Collecting the cell culture supernatant and purifying it to obtain the recombinant chimeric antigen.

13. An immunogenic composition comprising a first component and a second component, wherein the first component and the second component are not the same, and at least one component is selected from the recombinant chimeric antigen described in any one of claims 1-9.

14. A recombinant protein vaccine for the new coronavirus, comprising the recombinant chimeric antigen described in any one of claims 1 to 9, or the immunogenic composition described in claim 13, and an adjuvant; the adjuvant is selected from one or any combination of aluminum adjuvant, lipopolysaccharide, saponin, PolyI:C, CpG and emulsion adjuvant.

15. A new coronavirus recombinant nucleic acid vaccine comprising the recombinant nucleic acid described in claim 10.

16. Use of the recombinant chimeric antigen according to any one of claims 1 to 9, the recombinant nucleic acid according to claim 10, the host cell according to claim 11, the immunogenic composition according to claim 13, the new coronavirus recombinant protein vaccine according to claim 14, and the new coronavirus recombinant nucleic acid vaccine according to claim 15 in the preparation of a medicament for preventing new coronavirus infection.